Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex Biologics Announces Publication of a Real-World Evidence Study Demonstrating Superior or Similar Outcomes for Cygnus® Amnion-Based Skin Substitutes in Wound Care

MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leading medical technology company, developing and delivering innovative allografts for musculoskeletal and wound-care applications,...
September 30, 2025 08:30 ET | Source: Vivex Biologics, Inc.

Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease

MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S....
July 29, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND...
June 10, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex® Biologics, Inc. Appoints Industry Veteran Jon E. Block, Ph.D., as Chief Clinical Officer

MIAMI, June 10, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the appointment of Jon E. Block, Ph.D., an industry...
May 16, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award

MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company’s Executive Chairman, John A. McCallum, has...
April 08, 2025 08:00 ET | Source: Vivex Biologics, Inc.

Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its...
June 11, 2020 16:51 ET | Source: Vivex Biologics, Inc.

VIVEX Biologics Announces Presentation of Clinical Results of VIA Disc® at The Orthobiologic Institute (TOBI) Virtual Symposium

First large randomized controlled trial to demonstrate clinically significant and objective benefit from treating the disc, the most common source of back pain Initial safety results recently...
May 19, 2020 10:17 ET | Source: Vivex Biologics, Inc.

VIVEX Biologics Announces Presentation of Clinical Results of VIA Disc® During Webinar Series Hosted by The American Society of Pain & Neuroscience (ASPN)

First large randomized controlled trial to demonstrate clinically significant and objective benefit from treating the disc, the most common source of back pain Presentation to be part of continuing...
April 30, 2020 10:17 ET | Source: Vivex Biologics, Inc.

VIVEX Biologics Publishes Initial Clinical Results of VIA Disc in The International Journal of Spine Surgery

First-ever published 12-month results from Level 1 intradiscal study for treating patients with one or two level symptomatic degenerative disc disease Early evidence suggests greater than 70%...
February 20, 2020 10:17 ET | Source: Vivex Biologics, Inc.

VIVEX Biologics, Inc. Announces Multiple Presentations at the International Society for the Advancement of Spine Surgery (ISASS) 2020 Meeting

Industry-leading KOLs to present data from studies of multiple VIVEX technologies Presentations to showcase VIVEX products’ capacities to promote healing and bone fusion in certain spinal disorders ...